Sidley Represents Simcere in €1 Billion Licensing and Collaboration Agreement With Boehringer Ingelheim

Sidley represented Simcere Pharmaceutical Group Ltd. (HKEX: 2096) in a license and collaboration agreement with Boehringer Ingelheim for the development and commercialization of SIM0709, a pre-clinical bispecific antibody developed by Simcere for the treatment of inflammatory bowel disease (IBD). Under the agreement, Simcere is eligible to receive an upfront payment as well as milestone payments of up to €1.058 billion and royalties, and Boehringer receives global rights to the asset outside of greater China. This strategic partnership aims to accelerate and advance a treatment option that could improve outcomes for patients worldwide affected by IBD.

The Sidley team was led by Adam Welland (Technology and Life Sciences Transactions) and included Feifei Bian (Emerging Companies and Venture Capital), Torrey Cope and Chen Yang (Food, Drug and Medical Device), and Sabrina Glavota (Technology and Life Sciences Transactions).